EA201991227A1 - ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20 - Google Patents
ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20Info
- Publication number
- EA201991227A1 EA201991227A1 EA201991227A EA201991227A EA201991227A1 EA 201991227 A1 EA201991227 A1 EA 201991227A1 EA 201991227 A EA201991227 A EA 201991227A EA 201991227 A EA201991227 A EA 201991227A EA 201991227 A1 EA201991227 A1 EA 201991227A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- bind
- antigen binding
- binding molecules
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
Abstract
Настоящее изобретение относится к антителам, которые связываются с CD3, и к способам их использования. Согласно определенным вариантам осуществления антитела по изобретению связываются с CD3 человека с высокой аффинностью и индуцируют пролиферацию T-клеток человека. Изобретение относится к антителам, которые связываются с CD3 и индуцируют опосредованный T-клетками цитолиз опухолевых клеток. Согласно определенным вариантам осуществления настоящее изобретение относится к биспецифическим антигенсвязывающим молекулам, содержащим первый антигенсвязывающий домен, который специфически связывается с CD3 человека, и вторую антигенсвязывающую молекулу, которая специфически связывается с CD20 человека. В определенных вариантах осуществления биспецифические антигенсвязывающие молекулы по настоящему изобретению способны ингибировать рост B-клеточных опухолей, экспрессирующих CD20. Антитела и биспецифические антигенсвязывающие молекулы по изобретению подходят для лечения заболеваний и нарушений, при которых желательным и/или терапевтически эффективным является активированный или индуцированный целевой иммунный ответ. Например, антитела по изобретению подходят для лечения различных злокачественных опухолей, а также других связанных с CD20 заболеваний и нарушений.The present invention relates to antibodies that bind to CD3, and to methods for using them. In certain embodiments, the antibodies of the invention bind to human CD3 with high affinity and induce proliferation of human T cells. The invention relates to antibodies that bind to CD3 and induce T-cell mediated tumor cell cytolysis. In certain embodiments, the present invention relates to bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds to human CD3, and a second antigen binding molecule that specifically binds to human CD20. In certain embodiments, the bispecific antigen binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. Antibodies and bispecific antigen binding molecules of the invention are suitable for the treatment of diseases and disorders in which an activated or induced target immune response is desirable and / or therapeutically effective. For example, the antibodies of the invention are suitable for the treatment of various malignant tumors, as well as other CD20 related diseases and disorders.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361827098P | 2013-05-24 | 2013-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991227A1 true EA201991227A1 (en) | 2020-02-28 |
Family
ID=69636657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991227A EA201991227A1 (en) | 2013-05-24 | 2013-09-19 | ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20 |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201991227A1 (en) |
-
2013
- 2013-09-19 EA EA201991227A patent/EA201991227A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200237A1 (en) | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof | |
EA201890368A1 (en) | ANTIBODIES AGAINST PSMA, BISPECIFIC ANTIGENSELATING MOLECULES THAT BIND PSMA AND CD3 AND THEIR APPLICATION | |
EA201691858A1 (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
EA201890785A1 (en) | OPTIMIZED BISPECIFIC ANTI-CD3 ANTIBODIES AND THEIR APPLICATION | |
EA202191580A1 (en) | SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION | |
EA201990781A1 (en) | ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION | |
MX2022012083A (en) | Multispecific antigen-binding molecules and uses thereof. | |
MY197218A (en) | Multispecific antigen-binding molecules and uses thereof | |
PH12021551238A1 (en) | Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof | |
EA201490957A1 (en) | TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY | |
MX2021015271A (en) | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation. | |
EA201991227A1 (en) | ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20 | |
EA202090303A2 (en) | COMPOSITIONS OF ANTIBODIES FOR TREATMENT OF TUMORS | |
EA202190089A1 (en) | SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS | |
EA202191677A1 (en) | SPECIFIC ANTI-MUC16 X ANTI-CD28 ANTI-BODIES AND VARIANTS OF THEIR APPLICATION | |
EA202190314A1 (en) | BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND METHODS OF THEIR APPLICATION | |
EA201990779A1 (en) | SPECIFIC ANTI-MUC16-CD3 ANTIBODIES AND CONJUGATES ANTI-MUC16-MEDICINE | |
AR099798A1 (en) | METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT |